Ion beam tracking using ultrasound motion detection

Prall, M.; Kaderka, Robert; Saito, N.; Graeff, Christian; Bert, Christoph; Durante, Marco; Parodi, Katia; Schwaab, Julia; Sarti, Cristina; Jenne, Jürgen

doi:10.1118/1.4868459

Cited by 31 publications

(40 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A phantom-based experiment has shown that real-time ultrasound motion detection and beam tracking enable considerably reducing the interplay effects in scanned ion beam radiotherapy. 62 Apart from the ultrasound beam former and conventional diagnostic probe, the tested device consisted of a special tracking probe with two 5.5-MHz, 64-element phased-array ultrasound transducers encompassing two perpendicular image planes. 62 The tracking frame rate of 6.7 Hz (150 ms per frame) of the ultrasound probe was influenced by several factors such as the finite speed of sound and the time required for image processing.…”

Section: External Surrogatementioning

confidence: 99%

Particle therapy of moving targets—the strategies for tumour motion monitoring and moving targets irradiation

Kubiak¹

2016

BJR

View full text Add to dashboard Cite

Particle therapy of moving targets is still a great challenge. The motion of organs situated in the thorax and abdomen strongly affects the precision of proton and carbon ion radiotherapy. The motion is responsible for not only the dislocation of the tumour but also the alterations in the internal density along the beam path, which influence the range of particle beams. Furthermore, in case of pencil beam scanning, there is an interference between the target movement and dynamic beam delivery. This review presents the strategies for tumour motion monitoring and moving target irradiation in the context of hadron therapy. Methods enabling the direct determination of tumour position (fluoroscopic imaging of implanted radio-opaque fiducial markers, electromagnetic detection of inserted transponders and ultrasonic tumour localization systems) are presented. Attention is also drawn to the techniques which use external surrogate motion for an indirect estimation of target displacement during irradiation. The role of respiratory-correlated CT [four-dimensional CT (4DCT)] in the determination of motion pattern prior to the particle treatment is also considered. An essential part of the article is the review of the main approaches to moving target irradiation in hadron therapy: gating, rescanning (repainting), gated rescanning and tumour tracking. The advantages, drawbacks and development trends of these methods are discussed. The new accelerators, called "cyclinacs", are presented, because their application to particle therapy will allow making a breakthrough in the 4D spot scanning treatment of moving organs.

show abstract

Section: External Surrogatementioning

confidence: 99%

Particle therapy of moving targets—the strategies for tumour motion monitoring and moving targets irradiation

Kubiak¹

2016

BJR

View full text Add to dashboard Cite

show abstract

“…Relative to X‐ray based techniques, the use of US for intra‐fraction motion management is at an early stage. In particle therapy the feasibility of ultrasound based beam tracking has been reported by Prall et al . They showed that delay compensation is possible via neural networks and present experimental data indicating the feasibility of ultrasound based compensation without tracking parameters from treatment planning.…”

Section: Motion Monitoring Image Guided Particle Therapymentioning

confidence: 64%

Motion management in particle therapy

Mori¹,

Knopf

Umegaki

2018

Medical Physics

View full text Add to dashboard Cite

In this review article, we introduced the importance of “motion management” in advanced particle therapy. Several publications have reported that organ motion causes dose distribution disturbances due to interplay and blurring effects. Furthermore, motion can result in target dose miss and unwanted dose to healthy structures around the target. To avoid these problems, motion should be assessed and monitored prior and during treatment. In this review article, we give an overview about clinically available motion monitoring systems. Based on the acquired motion information an adequate motion mitigation technique should be chosen. This article reviews the clinical status of motion mitigation techniques like rescanning, gating and tracking. A limited number of centers have now started the treatment of targets in the thorax and abdomen using scanned particle beams. Therefore, the establishment of guidelines for motion monitoring and motion mitigation will be essential in the coming years.

show abstract

“…Information on the lag time of a motion detection system would be required if motion-adaptive actions are taken based on this system. So far, ultrasound imaging has been shown to be feasible to guide motion compensation with ion beam tracking 41 and multileaf collimator tracking. 22 Both studies used simple rigid spheres moved in water tanks as targets.…”

Section: Discussionmentioning

confidence: 99%

ELPHA: Dynamically deformable liver phantom for real‐time motion‐adaptive radiotherapy treatments

et al. 2019

View full text Add to dashboard Cite

Purpose Real‐time motion‐adaptive radiotherapy of intrahepatic tumors needs to account for motion and deformations of the liver and the target location within. Phantoms representative of anatomical deformations are required to investigate and improve dynamic treatments. A deformable phantom capable of testing motion detection and motion mitigation techniques is presented here. Methods The dynamically dEformable Liver PHAntom (ELPHA) was designed to fulfill three main constraints: First, a reproducibly deformable anatomy is required. Second, the phantom should provide multimodality imaging contrast for motion detection. Third, a time‐resolved dosimetry system to measure temporal effects should be provided. An artificial liver with vasculature was casted from soft silicone mixtures. The silicones allow for deformation and radiographic image contrast, while added cellulose provides ultrasonic contrast. An actuator was used for compressing the liver in the inferior direction according to a prescribed respiratory motion trace. Electromagnetic (EM) transponders integrated in ELPHA help provide ground truth motion traces. They were used to quantify the motion reproducibility of the phantom and to validate motion detection based on ultrasound imaging. A two‐dimensional ultrasound probe was used to follow the position of the vessels with a template‐matching algorithm. This detected vessel motion was compared to the EM transponder signal by calculating the root‐mean‐square error (RMSE). ELPHA was then used to investigate the dose deposition of dynamic treatment deliveries. Two dosimetry systems, radio‐chromic film and plastic scintillation dosimeters (PSD), were integrated in ELPHA. The PSD allow for time‐resolved measurement of the delivered dose, which was compared to a time‐resolved dose of the treatment planning system. Film and PSD were used to investigate dose delivery to the deforming phantom without motion compensation and with treatment‐couch tracking for motion compensation. Results ELPHA showed densities of 66 and 45 HU in the liver and the surrounding tissues. A high motion reproducibility with a submillimeter RMSE (<0.32 mm) was measured. The motion of the vasculature detected with ultrasound agreed well with the EM transponder position (RMSE < 1 mm). A time‐resolved dosimetry system with a 1 Hz time resolution was achieved with the PSD. The agreement of the planned and measured dose to the PSD decreased with increasing motion amplitude: A dosimetric RMSE of 1.2, 2.1, and 2.7 cGy/s was measured for motion amplitudes of 8, 16, and 24 mm, respectively. With couch tracking as motion compensation, these values decreased to 1.1, 1.4, and 1.4 cGy/s. This is closer to the static situation with 0.7 cGy/s. Film measurements showed that couch tracking was able to compensate for motion with a mean target dose within 5% of the static situation (−5% to +1%), which was higher than in the uncompensated cases (−41% to −1%). Conclusions ELPHA is a deformable liver phantom with high motion reproducibility. It was demonstrated t...

show abstract

Ion beam tracking using ultrasound motion detection

Cited by 31 publications

References 19 publications

Particle therapy of moving targets—the strategies for tumour motion monitoring and moving targets irradiation

Particle therapy of moving targets—the strategies for tumour motion monitoring and moving targets irradiation

Motion management in particle therapy

ELPHA: Dynamically deformable liver phantom for real‐time motion‐adaptive radiotherapy treatments

Contact Info

Product

Resources

About